Given that ∼90% of relapses in pediatric AML occur within 2 years of diagnosis [22], our results suggest that patients receiving LDC/G-CSF or SDC for remission induction appear to have similar outcomes. This evidence concerns the gene CSF3 and acute myeloid leukemia.